文献速递中医内科中药与中成药合理使用

清心解郁颗粒用于稳定性冠心病患者的QUEST多中心双盲随机试验

Qing-Xin-Jie-Yu Granule for patients with stable coronary artery disease (QUEST Trial): A multicenter, double-blinded, randomized trial.
PubMed 文献 · Complement Ther Med · 2019-10-09

QUEST试验纳入1500例稳定性冠心病患者,随机分为清心解郁颗粒组与安慰剂组各半,治疗6个月并随访6个月。中位随访12个月时主要复合终点无显著差异,但包含心血管死亡、非致命性心肌梗死和缺血性卒中的复合硬终点绝对风险降低0.99%,两组不良事件无差异。

要点

  • 稳定性冠心病标准治疗基础上加用清心解郁颗粒未显著改善主要复合终点。
  • 复合硬终点(心血管死亡、非致命性心梗、缺血性卒中)绝对风险降低0.99%。
  • 两组不良事件无差异,提示加用清心解郁颗粒安全性可接受。

核心结论

  • 在稳定性冠心病患者中,标准治疗加用清心解郁颗粒与降低非致命性心肌梗死及复合硬终点风险相关。

研究设计与样本

  • 多中心、双盲、随机对照试验,共纳入1500例有明确稳定性冠心病记录的患者,按1:1随机分配至清心解郁颗粒组或安慰剂组,治疗6个月并继续随访6个月。

主要发现

  • 中位随访12个月时,主要复合终点(心血管死亡、非致命性心肌梗死和冠状动脉血运重建)两组无显著差异(1.59% vs 1.62%;HR 0.41;95%CI 0.13-1.28)。
  • 复合硬终点(心血管死亡、非致命性心肌梗死和缺血性卒中)绝对风险降低0.99%(0.31% vs 1.30%;HR 0.06;95%CI 0.01-0.53)。
  • 两组不良事件无差异。

临床怎么用

  • 对于稳定性冠心病患者,在标准二级预防治疗基础上可考虑加用清心解郁颗粒以降低复合硬终点风险,但需结合个体情况评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIM: Despite optimal secondary preventive treatment, patients with stable coronary artery disease (SCAD) remain at high risk of cardiovascular events. This multicenter, double-blinded, randomized trial sought to determine whether the addition of Qing-Xin-Jie-Yu Granule (QXJYG), a traditional Chinese medicine prescription, to standard therapy would further reduce risk of cardiovascular events in patients with SCAD. METHODS: A total of 1500 patients with documented SCAD were randomly assigned in a 1:1 ratio to QXJYG or placebo for 6 months, and followed up for another 6 months. The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction (MI) and coronary revascularization. Near the end of the trial, but before unblinding, a commonly used composite 'hard' endpoint composed of cardiovascular death, nonfatal myocardial infarction and ischemic stroke was additionally analyzed. RESULTS: During a median follow-up of 12 months, no significant difference of the primary outcome between the two groups was observed (1.59% vs. 1.62%; hazard ratio, 0.41; 95% CI, 0.13-1.28). However, absolute risk of the composite 'hard' endpoint was reduced by 0.99% (0.31% vs. 1.30%; hazard ratio, 0.06; 95%CI, 0.01 to 0.53). No difference of adverse events between the two groups was observed. CONCLUSION: In patients with SCAD, the addition of QXJYG to standard therapy was associated with reduced risk of nonfatal MI and the composite 'hard' endpoint of cardiovascular death, nonfatal MI and stroke. (http://www.chictr.org.cn/showproj.aspx?proj=5200, ChiCTR-TRC-13004370).

来源:Complement Ther Med,查看原文。版权归原作者所有。

引用

  1. Li J, Gao Z, Zhang L, et al. Qing-Xin-Jie-Yu Granule for patients with stable coronary artery disease (QUEST Trial): A multicenter, double-blinded, randomized trial. Complement Ther Med. 2019. PMID: 31780034. doi:10.1016/j.ctim.2019.102209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。